AMGEN at the American College of Cardiology's (ACC) Annual Meeting

ACC 2022

April 2–4, Washington DC, Hybrid

Amgen is proud to be part of the American College of Cardiology's Annual Scientific Session & Expo in 2022. While you are here, you can explore the latest scientific information and disease state education from Amgen, and learn about Amgen's long-term commitment to developing and delivering transformative medicines for patients with cardiovascular disease.


Cardiometabolic Pipeline

PROFICIO Clinical Development Program-Introducing VESALIUS-CV

PROFICIO Clinical Development Program—Introducing VESALIUS-CV

Learn about PROFICIO, Amgen’s program of clinical studies of evolocumab. Introducing VESALIUS-CV, a global initiative exploring the potential of evolocumab for the prevention of first CV events. This is an investigational study. Evolocumab is not indicated for this intended use.


Please note: Some of the information on this page may pertain to investigational drugs.